AU2019310636B2 - Gene signatures for predicting metastasis of melanoma and patient prognosis - Google Patents

Gene signatures for predicting metastasis of melanoma and patient prognosis

Info

Publication number
AU2019310636B2
AU2019310636B2 AU2019310636A AU2019310636A AU2019310636B2 AU 2019310636 B2 AU2019310636 B2 AU 2019310636B2 AU 2019310636 A AU2019310636 A AU 2019310636A AU 2019310636 A AU2019310636 A AU 2019310636A AU 2019310636 B2 AU2019310636 B2 AU 2019310636B2
Authority
AU
Australia
Prior art keywords
individual
slnb
gene
signature
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019310636A
Other languages
English (en)
Other versions
AU2019310636A1 (en
Inventor
Domenico BELLOMO
Alexander MEVES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skylinedx Bv
Mayo Clinic in Florida
Original Assignee
Skylinedx BV
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skylinedx BV, Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Skylinedx BV
Publication of AU2019310636A1 publication Critical patent/AU2019310636A1/en
Application granted granted Critical
Publication of AU2019310636B2 publication Critical patent/AU2019310636B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/166Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019310636A 2018-07-25 2019-07-25 Gene signatures for predicting metastasis of melanoma and patient prognosis Active AU2019310636B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862703221P 2018-07-25 2018-07-25
US62/703,221 2018-07-25
US201862750294P 2018-10-25 2018-10-25
US62/750,294 2018-10-25
US201862778777P 2018-12-12 2018-12-12
US62/778,777 2018-12-12
PCT/NL2019/050487 WO2020022895A2 (en) 2018-07-25 2019-07-25 Gene signatures for predicting metastasis of melanoma and patient prognosis

Publications (2)

Publication Number Publication Date
AU2019310636A1 AU2019310636A1 (en) 2021-02-04
AU2019310636B2 true AU2019310636B2 (en) 2025-06-26

Family

ID=68242821

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019310636A Active AU2019310636B2 (en) 2018-07-25 2019-07-25 Gene signatures for predicting metastasis of melanoma and patient prognosis

Country Status (11)

Country Link
US (2) US12473599B2 (https=)
EP (1) EP3827101B1 (https=)
JP (1) JP7633159B2 (https=)
KR (1) KR20210044233A (https=)
CN (1) CN113039289B (https=)
AU (1) AU2019310636B2 (https=)
CA (1) CA3107401A1 (https=)
DK (1) DK3827101T3 (https=)
ES (1) ES2966015T3 (https=)
IL (1) IL280377A (https=)
WO (1) WO2020022895A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102751357B1 (ko) * 2021-07-16 2025-01-06 한림대학교 산학협력단 구강암의 임프절 전이 예측과 관련된 유전자군
WO2023107329A1 (en) * 2021-12-08 2023-06-15 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
AU2022406744A1 (en) * 2021-12-08 2024-07-11 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
WO2024108191A1 (en) * 2022-11-18 2024-05-23 University Of Virginia Patent Foundation Machine learning approach to predicting lymph node metastases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160222457A1 (en) * 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
US20070154889A1 (en) 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20060136145A1 (en) 2004-12-20 2006-06-22 Kuo-Jang Kao Universal reference standard for normalization of microarray gene expression profiling data
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
AU2007292219B2 (en) 2006-09-06 2014-04-24 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
AU2008247502A1 (en) 2007-05-04 2008-11-13 Dermtech International Diagnosis of melanoma by nucleic acid analysis
EP2191020A2 (en) 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
US20120128667A1 (en) 2009-05-01 2012-05-24 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
AU2011305696A1 (en) 2010-09-20 2013-05-02 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
WO2016025717A1 (en) * 2014-08-14 2016-02-18 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
MX388345B (es) 2016-05-10 2025-03-19 Mayo Found Medical Education & Res Métodos y materiales para estadificar cáncer de piel y seleccionar tratamiento.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160222457A1 (en) * 2012-11-14 2016-08-04 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions

Also Published As

Publication number Publication date
CN113039289A (zh) 2021-06-25
US12473599B2 (en) 2025-11-18
JP7633159B2 (ja) 2025-02-19
EP3827101B1 (en) 2023-11-08
WO2020022895A2 (en) 2020-01-30
NZ771988A (en) 2025-02-28
DK3827101T3 (da) 2023-12-11
EP3827101A2 (en) 2021-06-02
IL280377A (en) 2021-03-25
ES2966015T3 (es) 2024-04-17
KR20210044233A (ko) 2021-04-22
US20260071281A1 (en) 2026-03-12
WO2020022895A3 (en) 2020-04-02
CA3107401A1 (en) 2020-01-30
US20210301353A1 (en) 2021-09-30
JP2021531831A (ja) 2021-11-25
CN113039289B (zh) 2025-11-07
AU2019310636A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US20260071281A1 (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
Vachani et al. A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma
US10246748B2 (en) Biomarker combinations for colorectal tumors
AU2020202536B2 (en) Methods For Predicting Risk Of Metastasis In Cutaneous Melanoma
MX2013013746A (es) Biomarcadores para cancer de pulmon.
US11015190B2 (en) Method of treating a patient having renal cancer
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
US20120201750A1 (en) Serum biomarkers for melanoma metastasis
CN116936086A (zh) 乳腺癌远端转移风险预测基因模型的建构方法和风险预测方法
CN111315897B (zh) 用于黑素瘤检测的方法
HK40046957B (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
HK40046957A (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
CN116926190A (zh) 测量乳腺癌远端转移风险的预后标志物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)